Everpar Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.33M Buy
2,780
+102
+4% +$104K 0.95% 23
2026
Q1
$2.46M Sell
2,678
-363
-12% -$368K 0.85% 25
2025
Q4
$3.27M Buy
3,041
+301
+11% +$288K 1.21% 15
2025
Q3
$2.09M Buy
2,740
+499
+22% +$371K 0.83% 23
2025
Q2
$1.75M Sell
2,241
-261
-10% -$203K 0.79% 22
2025
Q1
$2.07M Sell
2,502
-178
-7% -$148K 1.1% 16
2024
Q4
$2.07M Buy
2,680
+17
+0.6% +$14.1K 1.04% 17
2024
Q3
$2.36M Sell
2,663
-75
-3% -$67.4K 1.22% 12
2024
Q2
$2.48M Buy
2,738
+185
+7% +$148K 1.24% 12
2024
Q1
$1.99M Sell
2,553
-612
-19% -$436K 1.21% 10
2023
Q4
$1.84M Buy
+3,165
New +$1.85M 0.86% 18

Other funds holding LLY

Everpar Advisors's LLY Position: Q2 2026 in Review

Everpar Advisors increased its Eli Lilly (LLY) stake by 3.8% in Q2 2026, buying an estimated $104K and bringing the position to 2,780 shares worth $3.33M. The position accounts for 0.95% of the portfolio, ranked #23.

Everpar Advisors first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 841 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Everpar Advisors held 2,780 shares of Eli Lilly worth $3.33M as of Q2 2026.
  • Everpar Advisors bought 102 Eli Lilly shares in Q2 2026, an estimated $104K.
  • Eli Lilly made up 0.95% of Everpar Advisors's portfolio in Q2 2026, its #23 holding.
  • Everpar Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 841 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Everpar Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.